Michael D. Sweat
Medical University of South Carolina
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael D. Sweat.
The Lancet | 2000
Michael D. Sweat; Steven E. Gregorich; Gloria Sangiwa; Colin Furlonge; Donald Balmer; Claudes Kamenga; Olga Grinstead; Thomas J. Coates
BACKGROUND Access to HIV-1 voluntary counselling and testing (VCT) is severely limited in less-developed countries. We undertook a multisite trial of HIV-1 VCT to assess its impact, cost, and cost-effectiveness in less-developed country settings. METHODS The cost-effectiveness of HIV-1 VCT was estimated for a hypothetical cohort of 10000 people seeking VCT in urban east Africa. Outcomes were modelled based on results from a randomised controlled trial of HIV-1 VCT in Tanzania and Kenya. Our main outcome measures included programme cost, number of HIV-1 infections averted, cost per HIV-1 infection averted, and cost per disability-adjusted life-year (DALY) saved. We also modelled the impact of targeting VCT by HIV-1 prevalence of the client population, and the proportion of clients who receive VCT as a couple compared with as individuals. Sensitivity analysis was done on all model parameters. FINDINGS HIV-1 VCT was estimated to avert 1104 HIV-1 infections in Kenya and 895 in Tanzania during the subsequent year. The cost per HIV-1 infection averted was US
Sexually Transmitted Diseases | 2003
Mark N. Lurie; Brian Williams; Khangelani Zuma; David Mkaya-Mwamburi; Geoff P. Garnett; Adriaan Willem Sturm; Michael D. Sweat; Joel Gittelsohn; Salim Safurdeen. Abdool Karim
249 and
American Journal of Public Health | 2002
Suzanne Maman; Jessie K. Mbwambo; Nora M. Hogan; Gad P. Kilonzo; Jacquelyn C. Campbell; Eugene Weiss; Michael D. Sweat
346, respectively, and the cost per DALY saved was
AIDS | 2003
Mark N. Lurie; Brian Williams; Khangelani Zuma; David Mkaya-Mwamburi; Geoff P. Garnett; Michael D. Sweat; Joel Gittelsohn; Salim Safurdeen. Abdool Karim
12.77 and
Aids and Behavior | 2008
Julie A. Denison; Kevin R. O’Reilly; George P. Schmid; Caitlin E. Kennedy; Michael D. Sweat
17.78. The intervention was most cost-effective for HIV-1-infected people and those who received VCT as a couple. The cost-effectiveness of VCT was robust, with a range for the average cost per DALY saved of
Aids Education and Prevention | 2009
Amy Medley; Caitlin E. Kennedy; Kevin O'Reilly; Michael D. Sweat
5.16-27.36 in Kenya, and
Journal of Acquired Immune Deficiency Syndromes | 2002
Salaam Semaan; Don C. Des Jarlais; Ellen Sogolow; Wayne D. Johnson; Larry V. Hedges; Gilbert Ramirez; Stephen A. Flores; Lisa R. Norman; Michael D. Sweat; Richard Needle
6.58-45.03 in Tanzania. Analysis of targeting showed that increasing the proportion of couples to 70% reduces the cost per DALY saved to
AIDS | 2003
Deanna Kerrigan; Jonathan M. Ellen; Luis Moreno; Santo Rosario; Joanne Katz; David D. Celentano; Michael D. Sweat
10.71 in Kenya and
Lancet Infectious Diseases | 2011
Michael D. Sweat; Stephen F. Morin; David D. Celentano; Marta Mulawa; Basant Singh; Jessie Mbwambo; Surinda Kawichai; Alfred Chingono; Gertrude Khumalo-Sakutukwa; Glenda Gray; Linda Richter; Michal Kulich; Andrew Sadowski; Thomas J. Coates
13.39 in Tanzania, and that targeting a population with HIV-1 prevalence of 45% decreased the cost per DALY saved to
Aids and Behavior | 2003
Suzanne Maman; Jessie Mbwambo; Nora M. Hogan; Ellen Weiss; Gad P. Kilonzo; Michael D. Sweat
8.36 in Kenya and